126 related articles for article (PubMed ID: 37642368)
1. STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling.
Wang L; Cao J; Tao J; Liang Y
Expert Opin Drug Saf; 2024 Mar; 23(3):277-286. PubMed ID: 37642368
[TBL] [Abstract][Full Text] [Related]
2. [IL-6 Regulates the Chemosensitivity of Drug-Resistant Multiple Myeloma Cell Lines to Bortezomib through STAT3/Notch Signaling Pathway].
Liu Y; Sui JZ; Zhu LH; Dai Y; Dong HQ; Cheng P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1474-1481. PubMed ID: 36208252
[TBL] [Abstract][Full Text] [Related]
3. [Icaritin Reverses Multidrug Resistance of Multiple Myeloma Cell Line KM3/BTZ].
Li ZY; Li ZJ; Chen X; Huang XR; Fang ZQ; Zhang JG; Fang J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1690-1695. PubMed ID: 29262899
[TBL] [Abstract][Full Text] [Related]
4. Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation.
Jin S; Li B; Zhang B; Gao X; Jia X; Xu L; Chang S; Hu K; Wang G; Xu Z; Zhang T; Song D; Yang G; Wu X; Zhu H; Huang C; Lu Y; Shi J; Zhu W; Chen G
Acta Biochim Biophys Sin (Shanghai); 2023 Dec; 55(12):1884-1891. PubMed ID: 38009004
[TBL] [Abstract][Full Text] [Related]
5. PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling.
Xu B; Li J; Xu D; Ran Q
Ir J Med Sci; 2023 Apr; 192(2):561-567. PubMed ID: 35508865
[TBL] [Abstract][Full Text] [Related]
6. [Cdc37 Contributes to bortezomib resistance in multiple myeloma via autophagy].
Liu LT; Deng SH; Zang MR; Zhang JQ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):583-588. PubMed ID: 32810966
[No Abstract] [Full Text] [Related]
7. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
Tang JX; Chen Q; Li Q; He YH; Xiao D
Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
[TBL] [Abstract][Full Text] [Related]
8. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
[TBL] [Abstract][Full Text] [Related]
9. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
[TBL] [Abstract][Full Text] [Related]
10. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b.
Fu Y; Liu X; Zhang F; Jiang S; Liu J; Luo Y
Cell Death Dis; 2019 Apr; 10(4):319. PubMed ID: 30967527
[TBL] [Abstract][Full Text] [Related]
12. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
[No Abstract] [Full Text] [Related]
13. [Effect of Bushen Yanggu Decoction on Multidrug Resistance of Multiple Myeloma Cell Line KM3/BTZ].
Li YP; Zhang JG; Fang ZQ; Huang XR; Chen X; Li ZJ; Fang J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):482-488. PubMed ID: 30998158
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
Jia C; Kong D; Guo Y; Li L; Quan L
Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
[TBL] [Abstract][Full Text] [Related]
15. CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma.
Liu J; Du F; Chen C; Li D; Chen Y; Xiao X; Hou X
Life Sci; 2020 Dec; 262():118506. PubMed ID: 33031827
[TBL] [Abstract][Full Text] [Related]
16. Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis.
Wang Y; Lin Q; Song C; Ma R; Li X
Cell Cycle; 2020 Dec; 19(23):3289-3302. PubMed ID: 33131409
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
18. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
19. MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner.
Liu Y; Cheng P; Zhao W; Zhu L; Sui J; Dai Y; Lai Y
Leuk Res; 2022 Mar; 114():106785. PubMed ID: 35074616
[TBL] [Abstract][Full Text] [Related]
20. Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib.
Sevilla-Movilla S; Arellano-Sánchez N; Martínez-Moreno M; Gajate C; Sánchez-Vencells A; Valcárcel LV; Agirre X; Valeri A; Martínez-López J; Prósper F; Mollinedo F; Teixidó J
J Pathol; 2020 Sep; 252(1):29-40. PubMed ID: 32501543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
